SCHEMBL5489349

SCHEMBL5489349

Cc1ccc(NC(=O)NC(=O)c2ccc3c(c2)OCCO3)cc1Cl

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 8/20 0.71
NPC1 O15118 7/20 0.71
MEN1 O00255 5/20 0.71
KMT2A Q03164 5/20 0.71
CASP3 P42574 2/20 0.71
SENP7 Q9BQF6 2/20 0.71
SENP6 Q9GZR1 1/20 0.71
CCR2 P41597 3/20 0.69
MAOB P27338 7/20 0.65
POLB P06746 3/20 0.64
SMN1; SMN2 Q16637 4/20 0.59
ALDH1A1 P00352 3/20 0.58
MAPT P10636 3/20 0.58
LMNA P02545 2/20 0.58
HTT P42858 1/20 0.58
HPGD P15428 2/20 0.58
CYP2C9 P11712 1/20 0.58
ALOX12 P18054 1/20 0.58
CYP2C19 P33261 1/20 0.58
NPSR1 Q6W5P4 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5489348 0.86 CCR2 (0.69) RAB9ANPC1MEN1KMT2ACCR2
SCHEMBL6180574 0.85 CCR2 (0.68) RAB9ANPC1MEN1KMT2ACCR2
SCHEMBL5497567 0.84 CCR2 (0.67) RAB9ANPC1MEN1KMT2ACCR2
SCHEMBL5491086 0.84 CCR2 (0.67) RAB9ANPC1MEN1KMT2ACCR2
SCHEMBL5491079 0.83 CCR2 (0.65) RAB9ANPC1MEN1KMT2ACCR2
SCHEMBL5493182 0.83 CCR2 (0.68) RAB9ANPC1MEN1KMT2ACCR2
SCHEMBL6184191 0.82 CCR2 (0.67) RAB9ANPC1MEN1KMT2ACASP3
SCHEMBL6180808 0.81 CCR2 (0.62) RAB9ANPC1MEN1KMT2ACASP3
SCHEMBL6179692 0.81 CCR2 (0.65) RAB9ANPC1MEN1KMT2ACASP3
SCHEMBL5491052 0.80 SMN1; SMN2 (0.60) RAB9ANPC1MEN1KMT2ACCR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7297696-B2 Antagonists of MCP-1 function and methods of use thereof TELIK, INC. (US) 2007-11-20 US disclosed
US-20050054668-A1 Antagonists of MCP-1 function and methods of use thereof LABORDE EDGARDO (US) 2005-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054668-A1 Antagonists of MCP-1 function and methods of use thereof CCR2, CCR1, CCL2 RAB9A 3249/4885NPC1 686/4885MEN1 2483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.